BeOne Medicines Ltd. — Director's Dealing 2019

Mar 12, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2019-03-07

Reporting Person: Huang Jane (CMO, Hematology)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-07	American Depositary Shares	S	71	$140.501	Disposed	0	Direct
2019-03-11	American Depositary Shares	M	2565	$29.49	Acquired	2565	Direct
2019-03-11	American Depositary Shares	S	2565	$130	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-11	Share Option (Right to Buy)	$2.27	M	33345	Acquired	2026-09-02	Ordinary Shares (33345.0)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	271621	Direct

Footnotes

F1: Each American Depositary Share ("ADS") represents 13 Ordinary Shares.

F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F3: These shares were acquired under the BeiGene, Ltd. Second Amended and Restated Employee Share Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

F4: The exercise price is reflected in ADSs.

F5: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares.

F6: These securities vest over a four-year period as follows: 25% on the first anniversary of September 2, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events.